Display options
Cite
Toricelli M, Melo FH, Peres GB, et al. Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer. 2015;14:161doi: 10.1186/s12943-015-0405-2.
Toricelli, M., Melo, F. H., Peres, G. B., Silva, D. C., & Jasiulionis, M. G. (2015). Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Molecular cancer, 14161. https://doi.org/10.1186/s12943-015-0405-2
Toricelli, Mariana, et al. "Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation." Molecular cancer vol. 14 (2015): 161. doi: https://doi.org/10.1186/s12943-015-0405-2
Toricelli M, Melo FH, Peres GB, Silva DC, Jasiulionis MG. Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer. 2015 Aug 22;14:161. doi: 10.1186/s12943-015-0405-2. PMID: 26297111; PMCID: PMC4546186.
Copy Download .nbib Format: NLM
Share it on

Mol Cancer. 2015 Aug 22;14:161. doi: 10.1186/s12943-015-0405-2.

Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.

Molecular cancer

Mariana Toricelli, Fabiana H M Melo, Giovani B Peres, Débora C P Silva, Miriam G Jasiulionis

Affiliations

  1. Pharmacology Department, Universidade Federal de São Paulo, São Paulo, Brazil.
  2. Microbiology, Immunology and Parasitology Department, Universidade Federal de São Paulo, São Paulo, Brazil.
  3. Biochemistry Department, Universidade Federal de São Paulo, São Paulo, Brazil.
  4. Ludwig Institute for Cancer Research, São Paulo, Brazil.
  5. Pharmacology Department, Universidade Federal de São Paulo, São Paulo, Brazil. [email protected].

PMID: 26297111 PMCID: PMC4546186 DOI: 10.1186/s12943-015-0405-2

[No abstract available.]

References

  1. Mol Cancer. 2013;12:22 - PubMed

Publication Types